AMG 761 is a humanized monoclonal antibody targeted to CCR4 positive T-cells.  AMG 761 binding leads to depletion of CCR4 positive T-cells.  AMG 761 is being investigated as a therapy for asthma. Amgen licensed this molecule from Kyowa Hakko Kirin Co., Ltd. in 2008.
 

This information is current as of February 5, 2010. Amgen’s product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen’s most recent Form 10-K and in Amgen’s periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.